NEW YORK, July 14, 2026, 13:08 (EDT)
- Intuitive Surgical shares fell 6.2% to $381.94 in early afternoon trading, erasing about $9.1 billion of market value.
- HCA Healthcare reported second-quarter declines of 2.3% in inpatient surgeries and 3.4% in outpatient surgeries. Intuitive reports results on Thursday.
- Five analyst target changes since Monday lowered their simple average by 8.8% to $543.20, still 42% above the stock.
Intuitive Surgical, Inc. NASDAQ:ISRG sank 6.2% on Tuesday, on the same day HCA Healthcare, Inc. NYSE:HCA disclosed falling surgical volumes, creating an unusually timely demand test before the robotic-surgery maker’s second-quarter report. The stock’s valuation of 46.4 times trailing earnings leaves little room for a soft utilization number.
HCA Chief Executive Sam Hazen said the hospital group remained confident it could “navigate through this dynamic environment.” But the operating figures were blunt: same-facility inpatient surgeries fell 2.3% and outpatient surgeries declined 3.4%, even as admissions rose 2.5% and emergency-room visits increased 3.6%. HCA linked part of the pressure to more uninsured patients and a weaker service mix. HCA Healthcare Investor Relations
Those figures do not map directly onto procedures performed with Intuitive’s da Vinci systems. Still, they challenge the assumption that surgical demand remains uniformly strong as insurance losses affect patient behavior and hospital finances. Timing matters here.
The damage was broad. HCA fell 7.6%, while procedure-sensitive medtech names Stryker Corporation NYSE:SYK and Medtronic plc NYSE:MDT lost 6.3% and 4.9%, respectively. The synchronized declines point to an industry discount, while fresh target cuts added company-specific pressure on Intuitive. The tape is sending two messages at once.
| Company | Intraday move | Trailing P/E | Intuitive premium |
|---|---|---|---|
| Intuitive Surgical NASDAQ:ISRG | -6.2% | 46.4x | — |
| Stryker NYSE:SYK | -6.3% | 35.9x | 29% |
| Medtronic NYSE:MDT | -4.9% | 22.2x | 109% |
P/E is the share price divided by the last 12 months of profit. Even after Tuesday’s decline, investors are paying 29% more for each dollar of Intuitive earnings than for Stryker’s, and more than twice Medtronic’s multiple. The market still prices Intuitive as the faster, steadier grower; it is simply demanding harder evidence.
That premium explains why five target revisions over Monday and Tuesday matter. Their simple average fell from $595.40 to $543.20, an 8.8% reduction, but the new figure remains about 42% above Tuesday’s price. Wall Street lowered the ceiling without abandoning the upside case.
| Analyst firm | Previous target | New target | Change | Rating |
|---|---|---|---|---|
| Baird | $610 | $525 | -13.9% | Outperform |
| TD Cowen / Toronto-Dominion Bank NYSE:TD | $585 | $520 | -11.1% | Buy |
| BTIG | $574 | $512 | -10.8% | Buy |
| RBC Capital Markets / Royal Bank of Canada NYSE:RY | $650 | $600 | -7.7% | Outperform |
| Goldman Sachs Group Inc. NYSE:GS | $558 | $559 | +0.2% | Buy |
| Simple average | $595.40 | $543.20 | -8.8% | — |
TD Cowen cited competition, remanufactured instruments, international markets and Intuitive’s valuation against peers. The firm said the second quarter could help the shares establish a floor if procedure growth and system performance remain strong, though one quarter would not settle the longer-term concerns. This is a reset, not capitulation.
Analysts expect second-quarter revenue of about $2.82 billion, up 15.6%, and earnings of $2.50 a share, up 14.2%. Intuitive’s first-quarter revenue grew 23% to $2.77 billion, meaning the consensus already assumes a marked slowdown. A routine beat may no longer be enough.
Revenue quality gives bulls a stronger argument. Recurring revenue reached $2.4 billion in the first quarter, or 86% of the total, while da Vinci instrument-and-accessory revenue per procedure increased to about $1,880 from $1,780. Chief Financial Officer Jamie Samath said: “Revenue growth ahead of total procedure growth reflects, in large part, the differentiated value of da Vinci 5.” That per-procedure figure may matter more than raw system deliveries. The Motley Fool
The consumables model is also changing. Intuitive said in May that five of six force-feedback instruments could be used 15 times rather than six, with the remaining instrument cleared for 10 uses. It also expects to extend the lives of some core instruments in 2027. That lowers hospitals’ cost per procedure but could alter the timing of instrument revenue, depending on product mix and usage. The economics sit inside the revenue-per-procedure number.
But HCA may prove a noisy signal. Intuitive’s da Vinci procedures grew 16% globally and 19% outside the United States last quarter, while HCA’s figures cover one operator and a far wider range of surgeries. The risk is that Intuitive has also flagged low tenders and pricing pressure in China, weak public-hospital finances in Japan, softer bariatric demand and tariff pressure. Its 67.5%-to-68.5% adjusted gross-margin forecast already includes a tariff hit equal to about 1% of revenue. Several small pressures could add up.
Investors will likely focus on four figures Thursday: da Vinci procedure growth against the 13.5%-to-15.5% annual guide, instrument revenue per procedure, da Vinci 5 placements and utilization, and adjusted gross margin. At 46 times earnings after a roughly $9 billion intraday value loss, reassurance is no longer enough. The market wants proof.
Related articles: NASDAQ:ISRG
